2-氟-3,4-二甲氧基苯甲酸 | 2967-96-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-氟-3,4-二甲氧基苯甲酸
• 英文名称: 2-fluoro-3,4-dimethoxybenzoic acid
• 英文别名: 2-fluoroveratric acid；2-fluoro-3,4-dimethoxy-benzoic acid；2-Fluor-3,4-dimethoxy-benzoesaeure
• CAS: 2967-96-6
• 化学式: C₉H₉FO₄
• 分子量: 200.166
• InChiKey: XKHNQEYSGMZRJI-UHFFFAOYSA-N

物化性质

• 沸点：
  290.9±35.0 °C(Predicted)
• 密度：
  1.298±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  55.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-氟-3,4-二甲氧基苯甲酸 在 N-溴代丁二酰亚胺(NBS) 、 氯化亚砜 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 1,4-二氧六环 、 甲醇 为溶剂， 反应 4.0h， 生成 2-fluoro-3,4-dimethoxyaniline
  参考文献：
  名称：

  Investigation of B,C-ring truncated deguelin derivatives as heat shock protein 90 (HSP90) inhibitors for use as anti-breast cancer agents

  摘要：

  On the basis of deguelin, a series of the B, C-ring truncated surrogates with N-substituted amide linkers were investigated as HSP90 inhibitors. The structure activity relationship of the template was studied by incorporating various substitutions on the nitrogen of the amide linker and examining their HIF-1 alpha inhibition. Among them, compound 57 showed potent HIF-1 alpha inhibition and cytotoxicity in triple-negative breast cancer lines in a dose-dependent manner. Compound 57 downregulated expression and phosphorylation of major client proteins of HSP90 including AKT, ERK and STAT3, indicating that its antitumor activity was derived from the inhibition of HSP90 function. The molecular modeling of 57 demonstrated that 57 bound well to the C-terminal ATP-binding pocket in the open conformation of the hHSP90 homodimer with hydrogen bonding and pi-cation interactions. Overall, compound 57 is a potential antitumor agent for triple-negative breast cancer as a HSP90 Cterminal inhibitor.

  DOI：

  10.1016/j.bmc.2019.02.040
• 作为产物：
  描述：

  1-氟-2,3-二甲氧基苯 在 盐酸 、 三氯化铝 、 溴 、 二乙胺 作用下， 以 氯仿 、 1,2-二氯乙烷 为溶剂， 反应 10.5h， 生成 2-氟-3,4-二甲氧基苯甲酸
  参考文献：
  名称：

  Stegmann, Hartmut B.; Deuschle, Gabriele; Schuler, Paul, Journal of the Chemical Society. Perkin transactions II, 1994, # 3, p. 547 - 556

  摘要：

  DOI：

文献信息

• SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES
  申请人：Snow Alan

  公开号：US20090060838A1

  公开（公告）日：2009-03-05

  Substituted n-aryl benzamides, related compounds and their pharmaceutically acceptable salts, their synthesis and labeling, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, including Aβ amyloidosis, such as observed in Alzheimer's disease, IAPP amyloidosis, such as observed in type 2 diabetes, and synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment are provided. Also provided is the use of the disclosed compounds as imaging agents and methods for in vivo imaging and diagnosis of amyloid and synuclein diseases.

  本发明提供了取代的n-芳基苯甲酰胺、相关化合物及其药学上可接受的盐、它们的合成和标记、含有它们的制药组合物以及它们在治疗淀粉样疾病中的应用，包括Aβ淀粉样蛋白病，如阿尔茨海默病，IAPP淀粉样蛋白病，如2型糖尿病，以及突触蛋白病，如帕金森病，并制造用于此类治疗的药物。本发明还提供了所述化合物作为成像剂的应用以及体内成像和诊断淀粉样和突触蛋白疾病的方法。
• MONOCYCLIC BETA-LACTAM COMPOUND AND USE THEREOF
  申请人：Evopoint Biosciences Co., Ltd.

  公开号：EP4074709A1

  公开（公告）日：2022-10-19

  Provided is a monocyclic β-lactam compound as shown in general formula (I), or an ester, a stereoisomer or a pharmaceutically acceptable salt thereof. Also provided are a pharmaceutical composition containing the monocyclic β-lactam compound as shown in general formula (I), or an ester, a stereoisomer or a pharmaceutically acceptable salt thereof, and the use thereof in the preparation of a drug for treating bacterial infections.

  本发明提供了通式（I）所示的单环β-内酰胺化合物，或其酯、立体异构体或药学上可接受的盐。还提供了一种含有通式（I）所示单环β-内酰胺化合物或其酯、立体异构体或药学上可接受的盐的药物组合物，以及其在制备治疗细菌感染药物中的用途。
• [EN] MONOCYCLIC β-LACTAM COMPOUND AND USE THEREOF<br/>[FR] NOUVEAU COMPOSÉ β-LACTAME MONOCYCLIQUE ET SON UTILISATION<br/>[ZH] 单环β-内酰胺化合物及其用途
  申请人：SUZHOU SINOVENT PHARMACEUTICALS CO LTD

  公开号：WO2021115444A1

  公开（公告）日：2021-06-17

  提供了一种通式(I)所示的单环-β内酰胺化合物或其酯、其立体异构体以及其药学上可接受的盐，还提供了包含通式(I)所示的单环-β内酰胺化合物或其酯、其立体异构体以及其药学上可接受的盐的药物组合物及其用于制备治疗细菌感染药物的用途
• Kaiser; Burger, Journal of the American Chemical Society, 1957, vol. 79, p. 4365,4369
  作者：Kaiser、Burger

  DOI：——

  日期：——
• Investigation of B,C-ring truncated deguelin derivatives as heat shock protein 90 (HSP90) inhibitors for use as anti-breast cancer agents
  作者：Ho Shin Kim、Van-Hai Hoang、Mannkyu Hong、Kyung Chul Kim、Jihyae Ann、Cong-Truong Nguyen、Ji Hae Seo、Hoon Choi、Jun Yong Kim、Kyu-Won Kim、Woong Sub Byun、Sangkook Lee、Seungbeom Lee、Young-Ger Suh、Jie Chen、Hyun-Ju Park、Tae-Min Cho、Ji Young Kim、Jae Hong Seo、Jeewoo Lee

  DOI：10.1016/j.bmc.2019.02.040

  日期：2019.4

  On the basis of deguelin, a series of the B, C-ring truncated surrogates with N-substituted amide linkers were investigated as HSP90 inhibitors. The structure activity relationship of the template was studied by incorporating various substitutions on the nitrogen of the amide linker and examining their HIF-1 alpha inhibition. Among them, compound 57 showed potent HIF-1 alpha inhibition and cytotoxicity in triple-negative breast cancer lines in a dose-dependent manner. Compound 57 downregulated expression and phosphorylation of major client proteins of HSP90 including AKT, ERK and STAT3, indicating that its antitumor activity was derived from the inhibition of HSP90 function. The molecular modeling of 57 demonstrated that 57 bound well to the C-terminal ATP-binding pocket in the open conformation of the hHSP90 homodimer with hydrogen bonding and pi-cation interactions. Overall, compound 57 is a potential antitumor agent for triple-negative breast cancer as a HSP90 Cterminal inhibitor.

表征谱图